Welcome to CSTR
Fall, 2008
General guidelines for your CSTR presentation:
The goal is to learn about topics that are “outside of the box”, like running a clinical trial, starting a company, patenting a result etc. Some sessions can be approached like TiMM—that is, one student covers a clinical review and the other student summarizes a specific scientific finding, drug, etc. Other sessions may require a different strategy, depending on the material and preceptor. Plan this strategy among yourselves and your preceptor. Feel free to discuss with Mitch, Skip or Emma.
Most sessions include two students. You and the other member(s) of your group should plan to meet as a group with your preceptor twice, the first time at least two weeks before the presentation. For preceptors who are offsite, you may need to schedule conference calls rather than meeting face to face. In this case, make sure that you email your preceptor(s) any presentations, outlines in advance. Although each member of the group is responsible for covering a specific part of the topic, you should work as a team and coordinate your presentations.
Your formal presentations should be concise and provide a basic framework for discussion. Assume that your classmates have read the material, but review the most important points. Summarize the reading material and show important data, but please do not review papers figure by figure, which will surely put you and your classmates to sleep! The total time for formal presentation should be about 30 minutes—15 minutes per student. This will leave the majority of time for informal discussion-- plan to guide, but not dominate this. You may want to pose some questions for the class and preceptor. You can review these questions with your preceptor in advance to gain some insight into how he/she would like you to direct the discussion.
Be creative! Have fun!
|
Class Date |
Faculty Preceptor |
Title |
Student 1 |
Student 2 |
|
Mon, Sept. 8 1412 BRB II/III |
Jennifer Lagenberger |
Intellectual Property |
|
|
|
Mon., Sept. 15 104 Stellar-Chance |
Rosemary Mazanet |
Application of Intellectual Property to drug development. |
|
|
|
Mon, Sept. 22 104 Stellar-Chance |
Jordan Orange |
Cytokine therapy in disease |
||
|
Tues, Sept. 30 104 Stellar-Chance |
Jean Bennett |
Gene therapy for congenital blindness |
| |
|
Tues, Oct. 7 John Morgan Wood Room |
Kathy High |
Gene Transfer for Hemophilia |
||
|
Mon, Oct. 13 1412 BRB II/III |
Don Siegel |
Targeted drug delivery to human skin using human single-chain antibody fragments |
||
|
Mon, Oct. 20 104 Stellar-Chance |
Carl June |
Genetically engineered lymphocytes for HIV and Cancer Therapy: Translational Take Home Lessons |
||
|
Mon, Oct 27 104 Stellar-Chance |
Barbara Weber & Tal Zaks |
EGFR inhibitors in cancer therapy: biological, study design, and regulatory implications. |
||
|
Tues, Nov. 4 1412 BRB II/III |
Brian Litt |
Implantable Devices to Treat Epilepsy |
||
|
Tues, Nov. 11 301 BRB II/III |
Paul Offit |
The Growing Threat of America's Anti-Vaccine Movement |
||
|
Mon, Nov. 17 1412 BRB II/III |
Robert Levy |
Developing novel heart valve replacements: Clinical, laboratory & corporate mechanisms. |
|
|
|
Mon, Nov. 24 1412 BRB II/III |
Dan Rader |
Genetics of lipids and translation to therapeutics |
| |
|
Mon, Dec. 1 1412 BRB II/III |
Robert Vonderheide |
Telomerase-based vaccines for cancer |
• Last updated: 06/20/2008